US.AMGN · Amgen

{
  "risk": {
    "level": "Low",
    "reason": "risk management score >= 8/10",
    "position": {
      "score": 1.8,
      "details": {
        "atrPct": 2.4387736980879624,
        "turnoverUsdM": 1148.675904696,
        "liquidityPoints": 0.8,
        "volatilityPoints": 1
      }
    },
    "rrPoints": 2.4,
    "stopLevels": {
      "symbol": "US.AMGN",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 334.1842,
      "strength_details": {
        "ma_score": 3,
        "atr_score": 2,
        "rsi_score": 3,
        "macd_score": 3,
        "volume_score": 2
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 2.2,
      "stop_loss_percent": 4.9,
      "take_profit_price": 389.1616,
      "target_multiplier": 2.5,
      "technical_strength": 2.65,
      "take_profit_percent": 10.8
    },
    "positionPoints": 1.8,
    "stopLossPoints": 2.4,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 2.214227586689854,
    "stopLossPercent": 4.877547396175925,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 96.5,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 69.5,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 27
  },
  "market": {
    "ma20": 333.4345,
    "ma50": 332.9022,
    "close": 351.32,
    "prevClose": 349.69,
    "avgVolume20": 2589980,
    "volumeRatio": 1.26,
    "changePercent": 0.47
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred+database-backfill-market-proxy"
  },
  "barCount": 150,
  "momentum": {
    "max": 50,
    "result": 27,
    "details": {
      "ret_5d": 0.06138975830815707,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 27,
      "vcp_bonus": 0,
      "vol_ratio": 1.3258019650221198,
      "ret_points": 12,
      "vol_points": 4,
      "range_ratio": 0.801198667912907,
      "volat_points": 0,
      "day_range_pct": 0.01798932545857557,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 8,
      "partial_history": false,
      "pullback_points": 1,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": true,
      "return_window_days": 5,
      "first_breakout_bonus": 2,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 96.5,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 4.8,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 96,
        "contribution": 4.8
      },
      {
        "raw": 16.4,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 82,
        "contribution": 16.4
      },
      {
        "raw": 10.2,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 68,
        "contribution": 10.2
      },
      {
        "raw": 2,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 10,
        "contribution": 2
      },
      {
        "raw": 8.6,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 86,
        "contribution": 8.6
      },
      {
        "raw": 23.5,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 78.33,
        "contribution": 23.5
      },
      {
        "raw": 4,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 40,
        "contribution": 4
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "checked",
  "standard110": {
    "rating": "謹慎買入",
    "result": 69.5,
    "details": [
      "基本面分析總分: 4.8/5分",
      "資金流分析總分: 16.4/20分",
      "市場環境分析總分: 10.2/15分",
      "催化劑分析: 2/20分",
      "風險管理總分: 8.6/10分",
      "技術信號分析總分: 23.5/30分",
      "情緒分析: 4/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 2,
      "基本面": 4.8,
      "資金流": 16.4,
      "市場環境": 10.2,
      "情緒分析": 4,
      "技術信號": 23.5,
      "風險管理": 8.6
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 2,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "catalystCount": 0
            }
          },
          "catalystPoints": 2
        }
      },
      "基本面": {
        "max": 5,
        "grade": "優秀",
        "items": {
          "pbPoints": 0.2,
          "pePoints": 0.4,
          "epsPoints": 0.75,
          "roePoints": 0.75,
          "debtPoints": 0.3,
          "marginPoints": 0.6,
          "turnoverUsdM": 1148.675904696,
          "volumePoints": 0.5,
          "revenuePoints": 0.4,
          "dividendPoints": 0.4,
          "marketCapPoints": 0.5
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "優秀",
        "items": {
          "cmfPoints": 3.2,
          "mfiPoints": 3.2,
          "obvPoints": 4,
          "vwapPoints": 4,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.AMGN",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "一般",
        "items": {
          "vix": {
            "score": 2.4,
            "details": {
              "source": "twelvedata+fred+database-backfill-market-proxy",
              "vixClose": 16.35
            }
          },
          "trend": {
            "score": 4,
            "details": {
              "qqq": {
                "ma20": 122.32855801433648,
                "ma50": 119.96346877259626,
                "name": "QQQ",
                "close": 124.13713218586749,
                "points": 2
              },
              "spy": {
                "ma20": 113.2768836882191,
                "ma50": 110.87278891017002,
                "name": "SPY",
                "close": 114.45487124539912,
                "points": 2
              },
              "source": "twelvedata+fred+database-backfill-market-proxy"
            }
          },
          "atrPct": 2.4387736980879624,
          "atrPoints": 3,
          "cciPoints": 0.8,
          "vixPoints": 2.4,
          "marketTrendPoints": 4
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "較差",
        "items": {
          "sentiment": {
            "score": 4,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "negativeHits": 0,
              "positiveHits": 2,
              "sentimentScoreRaw": 0.6
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 140670697,
                "url": "https://finnhub.io/api/news?id=ad2b84d6922374198644636fa5196b4dc2394bc855706d302f1a2ea8a86a4e3f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
                "category": "company",
                "datetime": 1781874003,
                "headline": "Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know"
              },
              {
                "id": 140658285,
                "url": "https://finnhub.io/api/news?id=ee7a5b7ac4483ba4d0c7f3f3ebc7018ccf6ddf7b404a5197ff8c757920a50392",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "The latest trading day saw Amgen (AMGN) settling at $341.66, representing a -1.78% change from its previous close.",
                "category": "company",
                "datetime": 1781733002,
                "headline": "Amgen (AMGN) Sees a More Significant Dip Than Broader Market: Some Facts to Know"
              },
              {
                "id": 140631035,
                "url": "https://finnhub.io/api/news?id=885b4350a27c6ba0f608a40b780696da8016c4c5e3022e8037eb137bcb4351cb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "With an annual dividend yield of 2.85%, Amgen Inc. (NASDAQ:AMGN) is included among the 12 High Yield Fortune 500 Stocks to Buy Now. Amgen Inc. (NASDAQ:AMGN) discovers, develops, manufactures, and delivers innovative medicines to fight some of the world’s toughest diseases. On June 10, Morgan Stanley analyst Terence Flynn raised the firm’s price target on […]",
                "category": "company",
                "datetime": 1781415445,
                "headline": "Morgan Stanley Raises Amgen (AMGN) Price Target Following a Strong Start for Uplizna"
              },
              {
                "id": 140626818,
                "url": "https://finnhub.io/api/news?id=44924ac05e8c985c1d34373a634245165f78a17d1e25ecb523c4dc0ead9f4726",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Amgen Inc. (NASDAQ:AMGN) is one of the 7 Best Longevity Stocks to Buy Now. On June 7, 2026, Amgen Inc. (NASDAQ:AMGN) announced new data at the American Diabetes Association 86th Scientific Sessions, including Phase 3 VESALIUS-CV subgroup results for Repatha in patients with high-risk diabetes and elevated LDL-C without prior heart attack or stroke. In […]",
                "category": "company",
                "datetime": 1781347176,
                "headline": "Here’s Why Amgen (AMGN) is Among the 7 Best Longevity Stocks to Buy Now"
              },
              {
                "id": 140613132,
                "url": "https://finnhub.io/api/news?id=901e979c9f44292670076abe49fe0b4113d4b97b662a6541b99d46bd97f95e64",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Amgen Inc. (NASDAQ:AMGN) is one of the top large cap value stocks to buy now. On June 7, Amgen presented new Phase 3 data from the VESALIUS-CV trial at the American Diabetes Association’s 86th Scientific Sessions, demonstrating that Repatha significantly reduces cardiovascular risk in patients with high-risk diabetes. In a subgroup of 6,002 patients with […]",
                "category": "company",
                "datetime": 1781207744,
                "headline": "Here is Why Amgen (AMGN) is One of the Top Large Cap Value Stocks to Buy Now"
              },
              {
                "id": 140607268,
                "url": "https://finnhub.io/api/news?id=0a19e79b0db39f910ac7048fc6c5f9c48621560683970e8b6f175640aa1907ed",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Is AMGN a good stock to buy? We came across a bullish thesis on Amgen Inc. on r/investing_discussion by Variant_Invest. In this article, we will summarize the bulls’ thesis on AMGN. Amgen Inc.’s share was trading at $344.57 as of June 9th. AMGN’s trailing and forward P/E were 23.98 and 15.48 respectively according to Yahoo Finance. Amgen […]",
                "category": "company",
                "datetime": 1781191515,
                "headline": "Is Amgen Inc. (AMGN) A Good Stock To Buy Now?"
              },
              {
                "id": 140600914,
                "url": "https://finnhub.io/api/news?id=edd6e4cd1e963366a4cb620ce1877491977d0fd1e4dbd65cea3d12d969fff68d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "In the closing of the recent trading day, Amgen (AMGN) stood at $337.5, denoting a -2.05% move from the preceding trading day.",
                "category": "company",
                "datetime": 1781128203,
                "headline": "Amgen (AMGN) Registers a Bigger Fall Than the Market: Important Facts to Note"
              },
              {
                "id": 140580295,
                "url": "https://finnhub.io/api/news?id=99e23d9c1b9127cecb94106a7d868dea449e9f74d7a5f786f80886afe28cae3d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Investors may be asking whether Amgen's share price still offers value at current levels, or if most of the opportunity is already reflected in the price. Amgen's stock last closed at US$345.73, with returns of 5.3% over 7 days, 4.2% over 30 days, 5.5% year to date, 21.4% over 1 year, 70.8% over 3 years, and 68.7% over 5 years. Recent attention on Amgen has focused on its position in large cap biotechnology and how market participants are evaluating the balance between its growth prospects...",
                "category": "company",
                "datetime": 1781010678,
                "headline": "Is It Too Late To Consider Amgen (AMGN) After Its Strong Multi Year Share Price Run?"
              }
            ],
            "raw_source": [
              {
                "id": 140672156,
                "url": "https://finnhub.io/api/news?id=316fd024f5fb9ffa66ea7460855c76ed20c567cbaf57adbbc1d65a5ba37927ed",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Amgen posts strong profits and cash flow, while NovoCure pursues growth with a direct-to-patient cancer therapy model and leaner balance sheet.",
                "category": "company",
                "datetime": 1781889034,
                "headline": "Amgen vs. NovoCure: Which Health Care Stock Is a Better Buy in 2026?"
              },
              {
                "id": 140670697,
                "url": "https://finnhub.io/api/news?id=ad2b84d6922374198644636fa5196b4dc2394bc855706d302f1a2ea8a86a4e3f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
                "category": "company",
                "datetime": 1781874003,
                "headline": "Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know"
              },
              {
                "id": 140667013,
                "url": "https://finnhub.io/api/news?id=40038816fa54cd490942c62bfb04c763452a018b9dcd1c1764d125cf2b04ce44",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "While investors fixate on the pipeline, a powerful and accelerating profit stream from its Sanofi collaboration is quietly reshaping the company's financial core.",
                "category": "company",
                "datetime": 1781830588,
                "headline": "How One Partnership Profit Line Reframes The Regeneron Pharmaceuticals Stock Story"
              },
              {
                "id": 140665981,
                "url": "https://finnhub.io/api/news?id=0b638c6ef191f5dbe4acd9d2334545c22003192c9ec27ab3ef212175c49ee56a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "The market is focused on Amgen's legacy drugs, but one number shows a new, faster-growing core business is already taking over.",
                "category": "company",
                "datetime": 1781816249,
                "headline": "What If Amgen Stock's Patent Worries Are Hiding Its Real Growth Engine?"
              },
              {
                "id": 140665144,
                "url": "https://finnhub.io/api/news?id=f5fec88a57b0f8f6e3f3ed8ccc4d70bc3f302670bff353663aed918740229c7c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Amgen's (AMGN) well diversified business with no specific product driving over 10% of the top-line,",
                "category": "company",
                "datetime": 1781811357,
                "headline": "Amgen's Diversified Business, Emerging Pipeline Drives Positive View, RBC Says"
              },
              {
                "id": 140664854,
                "url": "https://finnhub.io/api/news?id=042c3b1b649362c19ab9ef08adc4605f661781d63c4e6cfb25d95d99a481aa76",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "AMGN",
                "summary": "Get insights into the dow jones index performance on Thursday. Explore the top gainers and losers within the dow jones index in today's session.",
                "category": "company",
                "datetime": 1781809802,
                "headline": "Stay informed with the top movers within the dow jones index on Thursday."
              },
              {
                "id": 140671475,
                "url": "https://finnhub.io/api/news?id=04c7499d656cafdfb442d13e8677cc5baa001c9ba76b98009765eeed5ac4b408",
                "image": "https://image.cnbcfm.com/api/v1/image/108324290-17818192661781819251-46629128711-1080pnbcnews.jpg?v=1781819265&w=1920&h=1080",
                "source": "CNBC",
                "related": "AMGN",
                "summary": "Michael Yee, UBS global head of biotech research, joins 'Fast Money' to talk the biotech sector.",
                "category": "company",
                "datetime": 1781805250,
                "headline": "Surge in biotech being driven by M&A, says UBS's Michael Yee"
              },
              {
                "id": 140663697,
                "url": "https://finnhub.io/api/news?id=cfd7591aeb47ea7d17a131f977bc09b5b9a674d16cce3c54f5b2ea1d24765b3d",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "AMGN",
                "summary": "Stay updated with the movement of dow jones stocks in today's session. Discover which dow jones stocks are making waves on Thursday.",
                "category": "company",
                "datetime": 1781800802,
                "headline": "Uncover the latest developments among dow jones stocks in today's session."
              },
              {
                "id": 140658285,
                "url": "https://finnhub.io/api/news?id=ee7a5b7ac4483ba4d0c7f3f3ebc7018ccf6ddf7b404a5197ff8c757920a50392",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "The latest trading day saw Amgen (AMGN) settling at $341.66, representing a -1.78% change from its previous close.",
                "category": "company",
                "datetime": 1781733002,
                "headline": "Amgen (AMGN) Sees a More Significant Dip Than Broader Market: Some Facts to Know"
              },
              {
                "id": 140655827,
                "url": "https://finnhub.io/api/news?id=e734e787c4df5d3cf8302aedf4c81bc1e4fd9794caf9a3ca0ca1943862d62fa9",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "AMGN",
                "summary": "Get insights into the dow jones index performance on Wednesday. Explore the top gainers and losers within the dow jones index in today's session.",
                "category": "company",
                "datetime": 1781723402,
                "headline": "Explore the top gainers and losers within the dow jones index in today's session."
              },
              {
                "id": 140656174,
                "url": "https://finnhub.io/api/news?id=2aa3c28a6316d21cd0b3a250dbcd7a34faab4f462d8a0077eef69088034ae1a7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Management raised the bar, the stock rocketed higher, and now everyone is wondering if this is the new normal or just a sugar high.",
                "category": "company",
                "datetime": 1781720514,
                "headline": "Eli Lilly Stock's Trillion-Dollar Question"
              },
              {
                "id": 140654917,
                "url": "https://finnhub.io/api/news?id=3479a53a3c41521f5112013d52988287bfd58f1873134916970c4bafd230ed97",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Like Lundbeck’s bocunebart, Vedana’s clinical pipeline targets PACAP – an approach that has shown varying levels of success in clinical trials thus far.",
                "category": "company",
                "datetime": 1781714392,
                "headline": "Vedana debuts with $46m to progress migraine therapies"
              },
              {
                "id": 140654836,
                "url": "https://finnhub.io/api/news?id=75650634439443a1b3278415e11c94f5fd9a43ed9188da817a87e5cdb95ed5fe",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Management once made manufacturing its top priority; now that the topic has gone quiet, it reveals just how much the company's multi-billion-dollar bet has fundamentally changed.",
                "category": "company",
                "datetime": 1781711865,
                "headline": "Everyone Is Watching Eli Lilly Stock's New Drugs. Here Is the Metric That Vanished"
              },
              {
                "id": 140647587,
                "url": "https://finnhub.io/api/news?id=01d2a0cfa0813fa012e940b08a4951ba6db02000d5e4d9fc470aacf9a714e2db",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "AMGN",
                "summary": "Curious about the top performers within the dow jones index one hour before the close of the markets on Tuesday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.",
                "category": "company",
                "datetime": 1781637003,
                "headline": "Top dow jones movers in Tuesday's session"
              },
              {
                "id": 140646076,
                "url": "https://finnhub.io/api/news?id=000ed306953c8e5fb64bca83018e7cfcfc0ec0fea0b65950540222ea86756a1e",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "AMGN",
                "summary": "Wondering what's happening in today's session for the dow jones index? Stay informed with the top movers within the dow jones index on Tuesday.",
                "category": "company",
                "datetime": 1781628002,
                "headline": "Stay informed with the top movers within the dow jones index on Tuesday."
              },
              {
                "id": 140645243,
                "url": "https://finnhub.io/api/news?id=6861c3fbb6eabc1bdccf109ef15bfac5aca2f3377fd455be31001d3f8e14969f",
                "image": "https://cdn.benzinga.com/files/images/story/2026/06/16/Analyst-Works-On-Personal-Computer-Showi.jpeg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "AMGN",
                "summary": "Top analysts changed ratings on top names, including Sunrun, enGene Therapeutics, Camp4 Therapeutics, PennyMac Financial, Dave & Buster's, Neumora Therapeutics, Extra Space Storage, & W. P. Carey. See full list here.",
                "category": "company",
                "datetime": 1781598385,
                "headline": "W.P. Carey To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Tuesday"
              },
              {
                "id": 140646011,
                "url": "https://finnhub.io/api/news?id=6fafb764a69448ecfb16c6a0ac52ab2985620ccb39e1ca6723ddb229d38e6ed1",
                "image": "",
                "source": "Benzinga",
                "related": "AMGN",
                "summary": "Mizuho  analyst Salim Syed   maintains Amgen (NASDAQ:AMGN) with a Neutral and raises the price target from $295 to $303.",
                "category": "company",
                "datetime": 1781597546,
                "headline": "Mizuho Maintains Neutral on Amgen, Raises Price Target to $303"
              },
              {
                "id": 140639467,
                "url": "https://finnhub.io/api/news?id=45d96341a355eed5c643fc24508153b0829c1da5af3f88702651d3714f07b3ec",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "AMGN",
                "summary": "Stay updated with the movement of dow jones stocks in today's session. Discover which dow jones stocks are making waves on Monday.",
                "category": "company",
                "datetime": 1781550603,
                "headline": "Discover which dow jones stocks are making waves on Monday."
              },
              {
                "id": 140634701,
                "url": "https://finnhub.io/api/news?id=56e15153b5d84cf074c84fa9a70d98ce8e42190d45298481c1a03e5d0a55f772",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Harbour BioMed (the \"Company\"; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today announced that a jury in the United States District Court for the District of Delaware has returned a decisive verdict in the Company's favor in the patent infringement lawsuit against Amgen Inc., and Teneobio, Inc. (an Amgen subsidiary) (together, \"Amgen\").The verdict represents a complete victory f",
                "category": "company",
                "datetime": 1781481660,
                "headline": "Harbour BioMed Secures Landmark Victory in U.S. Patent Infringement Case Against Amgen, Reshaping the Global Antibody Patent Landscape"
              },
              {
                "id": 140631035,
                "url": "https://finnhub.io/api/news?id=885b4350a27c6ba0f608a40b780696da8016c4c5e3022e8037eb137bcb4351cb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "With an annual dividend yield of 2.85%, Amgen Inc. (NASDAQ:AMGN) is included among the 12 High Yield Fortune 500 Stocks to Buy Now. Amgen Inc. (NASDAQ:AMGN) discovers, develops, manufactures, and delivers innovative medicines to fight some of the world’s toughest diseases. On June 10, Morgan Stanley analyst Terence Flynn raised the firm’s price target on […]",
                "category": "company",
                "datetime": 1781415445,
                "headline": "Morgan Stanley Raises Amgen (AMGN) Price Target Following a Strong Start for Uplizna"
              },
              {
                "id": 140631036,
                "url": "https://finnhub.io/api/news?id=a2ab59c8d6c74b50a73966a720173c1d7a8eb2ef3f39680e4e1735727a977f36",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "European Commission approves Amgen’s IMDYLLTRA for extensive stage small cell lung cancer, opening a new targeted immunotherapy option for patients in the region. FDA proposes withdrawing Tavneos from the U.S. market over data integrity and safety concerns, including reports of patient deaths. Amgen, NasdaqGS:AMGN, initiates an independent review with the Duke Clinical Research Institute to respond to the FDA’s findings and protect its autoimmune franchise. For investors watching...",
                "category": "company",
                "datetime": 1781410481,
                "headline": "Amgen Faces Dual Turning Point With IMDYLLTRA Gain And Tavneos Risk"
              },
              {
                "id": 140626818,
                "url": "https://finnhub.io/api/news?id=44924ac05e8c985c1d34373a634245165f78a17d1e25ecb523c4dc0ead9f4726",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Amgen Inc. (NASDAQ:AMGN) is one of the 7 Best Longevity Stocks to Buy Now. On June 7, 2026, Amgen Inc. (NASDAQ:AMGN) announced new data at the American Diabetes Association 86th Scientific Sessions, including Phase 3 VESALIUS-CV subgroup results for Repatha in patients with high-risk diabetes and elevated LDL-C without prior heart attack or stroke. In […]",
                "category": "company",
                "datetime": 1781347176,
                "headline": "Here’s Why Amgen (AMGN) is Among the 7 Best Longevity Stocks to Buy Now"
              },
              {
                "id": 140628197,
                "url": "https://finnhub.io/api/news?id=342f0d9583ccd219155d0d5f1f1ab0415c00289a89e45232b5ba2eb96d36b725",
                "image": "https://image.cnbcfm.com/api/v1/image/108222971-1762518699305-gettyimages-2244853460-AFP_83BD63X.jpeg?v=1770822987&w=1920&h=1080",
                "source": "CNBC",
                "related": "AMGN",
                "summary": "Drugmakers are betting they can crack into the obesity drug market that Novo Nordisk and Eli Lilly currently dominate.",
                "category": "company",
                "datetime": 1781337601,
                "headline": "Drugmakers race to find a place in the next wave of obesity drugs  "
              },
              {
                "id": 140628198,
                "url": "https://finnhub.io/api/news?id=d08b438a036546ffd6f36598cc75c1ad49c6d6297d84a39a42e49efc114b1546",
                "image": "https://image.cnbcfm.com/api/v1/image/108318105-1780924433940-gettyimages-2256411028-abnehmpille_heap3a.jpeg?v=1780924444&w=1920&h=1080",
                "source": "CNBC",
                "related": "AMGN",
                "summary": "Five years after Wegovy’s FDA approval, the obesity drug market has evolved rapidly. Novo Nordisk and Eli Lilly introduced GLP-1 pills to compete with the in-demand weight loss shots. Eli Lilly’s next-generation treatment retatrutide produced an average 28% body weight loss in clinical trials, the most ever seen from a weight loss drug. With Pfizer, Amgen, and Zealand Pharma developing new treatments, the weight loss market competition continues to grow rapidly to meet demand.",
                "category": "company",
                "datetime": 1781337301,
                "headline": "The next phase of the obesity drug race"
              },
              {
                "id": 140621316,
                "url": "https://finnhub.io/api/news?id=7799b4943b4070490c4c31469f624b75e45753e95bef0bca85f5be0499429bf9",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "AMGN",
                "summary": "Let's have a look at the top dow jones gainers and losers one hour before the close of the markets of today's session.",
                "category": "company",
                "datetime": 1781291402,
                "headline": "Stay informed with the top movers within the dow jones index on Friday."
              },
              {
                "id": 140621660,
                "url": "https://finnhub.io/api/news?id=f8b5833ae5cd5c0710eeadfbc082ec40dd987f82e4d361ab7dca811157ff0548",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Eli Lilly's obesity drug franchise is a juggernaut, but a surprisingly large share of its success relies on price-sensitive consumers.",
                "category": "company",
                "datetime": 1781285513,
                "headline": "The Catch Hiding In Eli Lilly Stock's Growth Story"
              },
              {
                "id": 140617425,
                "url": "https://finnhub.io/api/news?id=015323472c96442d0af8016f395c190c8802f9ec169bcdf8307894d1c76496cd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Amgen brings in Duke to review Tavneos data as FDA questions approval and safety concerns.",
                "category": "company",
                "datetime": 1781269770,
                "headline": "Amgen's $500 Million Tavneos Faces FDA Withdrawal Fight"
              },
              {
                "id": 140627914,
                "url": "https://finnhub.io/api/news?id=52a6a4bda7c48f36b9e044106fb12bfe9b4823a2e4b61520e2d1ae0ad6545f64",
                "image": "https://cdn.benzinga.com/files/images/story/2026/06/12/Amgen-Photo-by-JHVEPhoto-via-Shutterstoc.jpeg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "AMGN",
                "summary": "Amgen challenges FDA's proposed Tavneos withdrawal, seeks hearing, and cites independent Duke review of trial data.",
                "category": "company",
                "datetime": 1781269225,
                "headline": "Amgen Seeks FDA Hearing To Challenge Proposed Tavneos Withdrawal"
              },
              {
                "id": 140616546,
                "url": "https://finnhub.io/api/news?id=9aec43a641625d72ca7e24bc0fa335aef6022ac8a68cc22492ee500914c8eff5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "New cancer therapies may help fund dividend growth.",
                "category": "company",
                "datetime": 1781260500,
                "headline": "AbbVie Reports Promising New Clinical Updates. Here's What It Means for the Company's Dividend."
              },
              {
                "id": 140613132,
                "url": "https://finnhub.io/api/news?id=901e979c9f44292670076abe49fe0b4113d4b97b662a6541b99d46bd97f95e64",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Amgen Inc. (NASDAQ:AMGN) is one of the top large cap value stocks to buy now. On June 7, Amgen presented new Phase 3 data from the VESALIUS-CV trial at the American Diabetes Association’s 86th Scientific Sessions, demonstrating that Repatha significantly reduces cardiovascular risk in patients with high-risk diabetes. In a subgroup of 6,002 patients with […]",
                "category": "company",
                "datetime": 1781207744,
                "headline": "Here is Why Amgen (AMGN) is One of the Top Large Cap Value Stocks to Buy Now"
              },
              {
                "id": 140607999,
                "url": "https://finnhub.io/api/news?id=483a2b1c471e686399828835f37ce7066b4ab2b54cd1d47777945071f1502a8b",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "AMGN",
                "summary": "Curious about the top performers within the dow jones index in the middle of the day on Thursday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.",
                "category": "company",
                "datetime": 1781196002,
                "headline": "Discover which dow jones stocks are making waves on Thursday."
              },
              {
                "id": 140607268,
                "url": "https://finnhub.io/api/news?id=0a19e79b0db39f910ac7048fc6c5f9c48621560683970e8b6f175640aa1907ed",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Is AMGN a good stock to buy? We came across a bullish thesis on Amgen Inc. on r/investing_discussion by Variant_Invest. In this article, we will summarize the bulls’ thesis on AMGN. Amgen Inc.’s share was trading at $344.57 as of June 9th. AMGN’s trailing and forward P/E were 23.98 and 15.48 respectively according to Yahoo Finance. Amgen […]",
                "category": "company",
                "datetime": 1781191515,
                "headline": "Is Amgen Inc. (AMGN) A Good Stock To Buy Now?"
              },
              {
                "id": 140607060,
                "url": "https://finnhub.io/api/news?id=2e943f8b079d83dde925768b61908b0404f033c03851ff11731dff1e6c007893",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Prices for finished consumer goods, excluding food and energy, rose by 0.3% in May",
                "category": "company",
                "datetime": 1781181420,
                "headline": "Nasdaq semis stocks lead rebound rally despite Trump warning of new Iran strikes"
              },
              {
                "id": 140605362,
                "url": "https://finnhub.io/api/news?id=a0bf51eeadcf38be4766050653b2364018184702a664443821ec45d8f4818f0f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "The results support Takeda’s long-held belief in zasocitinib’s superiority and could help it gain a commercial advantage over Bristol’s therapy.",
                "category": "company",
                "datetime": 1781161200,
                "headline": "Takeda’s $4B TYK2 drug tops Bristol Myers’ Sotyktu in head-to-head test"
              },
              {
                "id": 140600914,
                "url": "https://finnhub.io/api/news?id=edd6e4cd1e963366a4cb620ce1877491977d0fd1e4dbd65cea3d12d969fff68d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "In the closing of the recent trading day, Amgen (AMGN) stood at $337.5, denoting a -2.05% move from the preceding trading day.",
                "category": "company",
                "datetime": 1781128203,
                "headline": "Amgen (AMGN) Registers a Bigger Fall Than the Market: Important Facts to Note"
              },
              {
                "id": 140598747,
                "url": "https://finnhub.io/api/news?id=d5de8df232feb1f3171e73f04ded1e620587bb48b4da75f4e61016474e5c9c37",
                "image": "",
                "source": "Benzinga",
                "related": "AMGN",
                "summary": "Morgan Stanley  analyst Terence Flynn   maintains Amgen (NASDAQ:AMGN) with a Equal-Weight and raises the price target from $332 to $340.",
                "category": "company",
                "datetime": 1781099635,
                "headline": "Morgan Stanley Maintains Equal-Weight on Amgen, Raises Price Target to $340"
              },
              {
                "id": 140595563,
                "url": "https://finnhub.io/api/news?id=438bb05c18cd8c2971864ab7745f5e6bb41374ad3447972b11e5e7eeac66001f",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/177281238/image_177281238.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "AMGN",
                "summary": "Roche vs Pfizer in the booming GLP-1 obesity/T2D market: Phase 2 enicepatide vs berobenatide claims, pipeline strength, and why Roche leads—read now.",
                "category": "company",
                "datetime": 1781099063,
                "headline": "Roche Vs. Pfizer: Obesity Week Presentations Deep Dive - What Investors Must Know"
              },
              {
                "id": 140592782,
                "url": "https://finnhub.io/api/news?id=93abfaccadab344e0367810b00066f2eec269112d6cd00042d371c411918a5aa",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "MariTide's less frequent dosing could help AMGN carve out a place in the rapidly expanding obesity drug market.",
                "category": "company",
                "datetime": 1781094540,
                "headline": "Can Amgen's MariTide Win Share in the Fast-Growing Obesity Market?"
              },
              {
                "id": 140595822,
                "url": "https://finnhub.io/api/news?id=ce891615efbe9fc7db1740816c434288f1c101e3136af06e6beb596251a353b5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Biogen has recently outperformed its industry peers, and analysts remain reasonably upbeat about the stock’s prospects.",
                "category": "company",
                "datetime": 1781089586,
                "headline": "How Is Biogen’s Stock Performance Compared to Other Biotech Stocks?"
              },
              {
                "id": 140595232,
                "url": "https://finnhub.io/api/news?id=913a9f67d8a00ebe7154b47aac2b6cd87b11911dad77c2df0b816a54a63afe70",
                "image": "https://image.cnbcfm.com/api/v1/image/108319194-1781041246459-1781039974566-3ED3-REQ-AMGEN-060926.jpg?v=1781041248&w=1920&h=1080",
                "source": "CNBC",
                "related": "AMGN",
                "summary": "At the American Diabetes Association’s 2026 Scientific Sessions, CNBC’s Angelica Peebles sat down with Amgen’s Executive Vice President of Obesity and Related Conditions, Susan Sweeney, who discussed the gamechanging potential of Amgen’s Maritide injection, as it’s currently being studied as a monthly injection and a 4-6x per year injection for obesity. She says that more infrequent dosing could be a better option for obese patients as it isn’t a daily reminder of their disease, like a daily pill.",
                "category": "company",
                "datetime": 1781026905,
                "headline": "Amgen Obesity Head: 90% of the obesity market is untreated"
              },
              {
                "id": 140584874,
                "url": "https://finnhub.io/api/news?id=1f4c087b2c44ca1cfdcf748e8790b150910bf2efa9437646ea0fda106e6ca111",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Nvidia, Visa and Microsoft lead the list of Wall Street's top Dow Jones stocks to buy now. Some other names might surprise you.",
                "category": "company",
                "datetime": 1781026172,
                "headline": "All 30 Dow Jones Stocks Ranked: Buy, Sell or Hold?"
              },
              {
                "id": 140581493,
                "url": "https://finnhub.io/api/news?id=fd84574843227b806f4e7e190f3ed196594f2d53b0794ba431d482694c8d9355",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Amgen (NASDAQ:AMGN) executives said the company’s first-quarter performance supports its view that 2026 can serve as a “springboard year,” with growth products helping offset increased competition for the denosumab franchise and other losses of exclusivity. Speaking at a Goldman Sachs event, Peter",
                "category": "company",
                "datetime": 1781017597,
                "headline": "Amgen Eyes 2026 ‘Springboard’ as Growth Drugs Offset Patent Pressure"
              },
              {
                "id": 140580295,
                "url": "https://finnhub.io/api/news?id=99e23d9c1b9127cecb94106a7d868dea449e9f74d7a5f786f80886afe28cae3d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Investors may be asking whether Amgen's share price still offers value at current levels, or if most of the opportunity is already reflected in the price. Amgen's stock last closed at US$345.73, with returns of 5.3% over 7 days, 4.2% over 30 days, 5.5% year to date, 21.4% over 1 year, 70.8% over 3 years, and 68.7% over 5 years. Recent attention on Amgen has focused on its position in large cap biotechnology and how market participants are evaluating the balance between its growth prospects...",
                "category": "company",
                "datetime": 1781010678,
                "headline": "Is It Too Late To Consider Amgen (AMGN) After Its Strong Multi Year Share Price Run?"
              },
              {
                "id": 140580296,
                "url": "https://finnhub.io/api/news?id=944e2225c11935b82b7ed9bd011617af0cebae870caf1542ab79e8f9f1b2ca05",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor execution, weak financials, or structural headwinds.",
                "category": "company",
                "datetime": 1781010614,
                "headline": "2 S&P 500 Stocks with Competitive Advantages and 1 Facing Challenges"
              },
              {
                "id": 140582056,
                "url": "https://finnhub.io/api/news?id=45943567e41e2183b2c141da75e933852f6f6d9d1dabf898bcf8cd4078c527aa",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "AMGN",
                "summary": "Amgen Inc. (AMGN) Goldman Sachs 47th Annual Global Healthcare Conference 2026 June 9, 2026 9:20 AM EDTCompany ParticipantsPeter Griffith - Executive VP...",
                "category": "company",
                "datetime": 1781009531,
                "headline": "Amgen Inc. (AMGN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript"
              },
              {
                "id": 140580297,
                "url": "https://finnhub.io/api/news?id=f873c24975228e4610b3870636f5d54f9708bfd96651429da5faac2a63050b80",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "EVERSANA®, a leading global provider of commercial services to the life sciences industry, today announced the expansion of its already leading market access offering with the appointment of Jen Norton as President, Market Access & Value. In this new role, Norton will lead the development of a dedicated, technology-first fully integrated market access business unit, uniting EVERSANA's comprehensive services to help clients navigate the complex global pricing and access landscape.",
                "category": "company",
                "datetime": 1781007360,
                "headline": "EVERSANA Strengthens Commitment to Driving Market Access Growth with Addition of Industry Expert Jen Norton"
              },
              {
                "id": 140579526,
                "url": "https://finnhub.io/api/news?id=a6dfe072f8696471d2fba41558b3d814d309673726395978172c9a7024bd3ea2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Antag Therapeutics Elects Keith Leonard as Chairman of its Board of Directors Copenhagen, Denmark, 09 June 2026 – Antag Therapeutics (“Antag” or “the Company”), advancing personalized and flexible obesity treatment through GIP receptor antagonism, today announces the election of Keith Leonard as Chairman of its Board of Directors. Keith is a highly experienced global biopharmaceutical executive with 30 years of industry experience leading companies and driving commercial strategies. Throughout h",
                "category": "company",
                "datetime": 1781002800,
                "headline": "Antag Therapeutics Elects Keith Leonard as Chairman of its Board of Directors"
              },
              {
                "id": 140577305,
                "url": "https://finnhub.io/api/news?id=6c73f97eb58f4b77dbb1734826a319d43cfc3ad8a41b2480b92309ffd39282c2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "With a net profit margin of 20.96%, Amgen Inc. (NASDAQ:AMGN) is included among the 10 Most Profitable Dividend Stocks to Invest In Now. On June 5, Goldman Sachs lowered its price recommendation on Amgen Inc. (NASDAQ:AMGN) to $389 from $425. It reiterated a Buy rating on the stock. The firm adjusted its model after Amgen disclosed […]",
                "category": "company",
                "datetime": 1780976299,
                "headline": "Goldman Sachs Trims Amgen (AMGN) Valuation but Sticks with Buy Rating"
              },
              {
                "id": 140574200,
                "url": "https://finnhub.io/api/news?id=c231254cf9bb4eb792a519edc2d69c2c6e85818ad128330e28bca83dff16073d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "More than a simple climb, the drugmaker's stock re-rated on a growth story that somehow keeps getting bigger.",
                "category": "company",
                "datetime": 1780948199,
                "headline": "Why Is Lilly Stock Growing Like A Silicon Valley Tech Darling?"
              },
              {
                "id": 140572134,
                "url": "https://finnhub.io/api/news?id=31059e393c810668d7bec5687df1d98ad5259d646d31695c90e183a11b5037a1",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "AMGN",
                "summary": "Stay informed about the performance of the dow jones index one hour before the close of the markets on Monday. Uncover the top gainers and losers in today's session for valuable insights.",
                "category": "company",
                "datetime": 1780945802,
                "headline": "Exploring the top movers within the dow jones index during today's session."
              },
              {
                "id": 140567632,
                "url": "https://finnhub.io/api/news?id=6f88882c41b453c0be4b24e293eb3af8074e15fd8a0eb4b5e7655d76e1d31b84",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Stock Market Today: The Dow Jones index rose Monday on Trump's latest Iran comments. Marvell stock surged on news that it'll join the S&P 500.",
                "category": "company",
                "datetime": 1780926508,
                "headline": "Stock Market Today: Dow Rallies On Trump, Iran Comments; Marvell Pops On S&P 500 Addition(Live Coverage)"
              },
              {
                "id": 140567759,
                "url": "https://finnhub.io/api/news?id=20d807a5d537447ac939b5e56888e9cd3631d45980fc7e809a38a7ea86e2ca58",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "The biotech giant is bucking the market trend, but its real value for investors lies in a story that unfolds over years, not days.",
                "category": "company",
                "datetime": 1780924024,
                "headline": "Can MariTide Save Amgen Stock From Its Fading Blockbusters?"
              },
              {
                "id": 140566973,
                "url": "https://finnhub.io/api/news?id=380066d393421a3ac1fb37616f364de6ff5a6c2cc2df68d88f8e56f32afa17b6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Protego Biopharma, Inc., a clinical-stage biotechnology company focused on developing small-molecule drugs that target protein misfolding diseases, today announced the appointment of Jae B. Kim, MD, as its Chief Medical Officer (CMO). Dr. Kim joins Protego after serving as Chief Medical Officer of Septerna since 2024.",
                "category": "company",
                "datetime": 1780916400,
                "headline": "Protego Biopharma Appoints Jae B. Kim, MD, as Chief Medical Officer"
              },
              {
                "id": 140570204,
                "url": "https://finnhub.io/api/news?id=8af80ffed1ce210172db0d8bf47a02b8e6e9867fdbb4c1de86bf284d4745c9e5",
                "image": "https://image.cnbcfm.com/api/v1/image/108226739-1763385616870-gettyimages-2221165792-INDIA_WEGOVY.jpeg?v=1763385675&w=1920&h=1080",
                "source": "CNBC",
                "related": "AMGN",
                "summary": "While the experimental drug met its key targets, analysts are concerned over the commercial opportunity due to side effects.",
                "category": "company",
                "datetime": 1780897205,
                "headline": "Weight loss drug maker sinks 23% after new safety data spooks investors"
              },
              {
                "id": 140562425,
                "url": "https://finnhub.io/api/news?id=e6d22ef377221ca52cc2d10bbaf1438fa51b84ffc1dcef5985c67e037ed3d50f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Amgen (NASDAQ:AMGN) today announced new data at the American Diabetes Association (ADA) 86th Scientific Sessions reinforcing its commitment to addressing unmet needs for people living with cardiometabolic conditions and improving patient outcomes.",
                "category": "company",
                "datetime": 1780865100,
                "headline": "AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS"
              },
              {
                "id": 140555214,
                "url": "https://finnhub.io/api/news?id=e5cffa8e6e10526be170c194a4cfb0256214d3e72ab5a96cd21ce8545c4381f3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "The oldest stock index in the world is suffering from a severe case of split personality. This internal friction has triggered a mechanical phenomenon, the likes of which I cannot recall, at least to this degree.",
                "category": "company",
                "datetime": 1780765202,
                "headline": "The Dow's Split Personality: Why Some Winners Soar While Others Drag Down the Dow"
              },
              {
                "id": 140551172,
                "url": "https://finnhub.io/api/news?id=f41fc68bd8d46fee462014c26e7c9b7399ea6e1a8e3acddc9b1191d61c46c6e3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Investors looking for the best tech ETF might be disappointed to discover that a lot of the Invesco QQQ ETF's portfolio isn't actually tech.",
                "category": "company",
                "datetime": 1780761900,
                "headline": "QQQ vs VGT: Which Tech ETF Is Better?"
              },
              {
                "id": 140549741,
                "url": "https://finnhub.io/api/news?id=28db6194f71b4be09a7ec5f22e9cac6ef5edf01828c51acf8a90a2dbb95d00c6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "The phrase sounds almost impossible: a short squeeze involving index funds. After all, index funds are designed to be passive, rules-based buyers, not active traders caught on the wrong side of a position. Yet that is exactly the scenario Animal Spirits hosts Michael Batnick and Ben Carlson laid out on Episode 467, “The Biggest Short ... SpaceX IPO Could Create ‘The Biggest Short Squeeze’ of All Time on Index Funds. Here’s How That Happens.",
                "category": "company",
                "datetime": 1780755027,
                "headline": "SpaceX IPO Could Create ‘The Biggest Short Squeeze’ of All Time on Index Funds. Here’s How That Happens."
              },
              {
                "id": 140546701,
                "url": "https://finnhub.io/api/news?id=06714d74589faa13d96d91b0750388d8ba8642cfd7d19093be0bc3043c75dc87",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Amgen stock snapshot and recent performance Amgen (AMGN) is drawing attention after recent price moves, with the stock last closing at US$349.58. Over the past month it gained about 5.6%, while over the past 3 months it declined roughly 5.4%. See our latest analysis for Amgen. The recent 1-day share price return of 1.15% and 7-day return of 3.8% build on a 30-day share price gain of 5.6%, while the 1-year total shareholder return of 24% and 3-year total shareholder return of about 75% point...",
                "category": "company",
                "datetime": 1780719842,
                "headline": "Assessing Whether Amgen (AMGN) Is Slightly Undervalued After Recent Share Price Gains"
              },
              {
                "id": 140544122,
                "url": "https://finnhub.io/api/news?id=7f12a13c39ecbcdd30f2566a129f3d2950f4311ff3d4e8263ced98ff27fa2e27",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Amgen (AMGN) stock is at an interesting point right now. If you bet on it, you are betting on a company that's growing reasonably, is sustaining good cash flow and margin, has a low-debt to market capital structure, and is relatively cheaply valued. But is that enough.",
                "category": "company",
                "datetime": 1780700116,
                "headline": "Is Amgen An Undervalued Stock Or Value Trap?"
              },
              {
                "id": 140544171,
                "url": "https://finnhub.io/api/news?id=719cf90c4b2b086c8a7bcd5463f1c329b5f329aa5e460de648fd3ad7680bf071",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Amgen Inc. (NASDAQ:AMGN) is one of the best cheap stocks to buy for beginners. Amgen Inc. (NASDAQ:AMGN) announced on June 1 that the European Commission granted marketing authorization for IMDYLLTRA® (tarlatamab) as a monotherapy for the treatment of adults with extensive-stage small cell lung cancer who require systemic therapy following disease progression on or after first-line […]",
                "category": "company",
                "datetime": 1780697101,
                "headline": "Amgen Inc. (AMGN) Announces EC’s Grant of Marketing Authorization for IMDYLLTRA®"
              },
              {
                "id": 140544121,
                "url": "https://finnhub.io/api/news?id=307d1f7c564bc21bcf4cb91267c79167a70fda1441b10462f42be835169b64fc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Quantinuum’s IPO grabbed headlines, but its first trading day showed both excitement and caution. How can investors approach QNT stock after its Wall Street debut?",
                "category": "company",
                "datetime": 1780678743,
                "headline": "How to Play QNT Stock After the Quantinuum IPO"
              },
              {
                "id": 140537117,
                "url": "https://finnhub.io/api/news?id=809cc7899f17b93e7809acf4549bbe5e66e1d40842132eb8d1159a155801f8d7",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "AMGN",
                "summary": "Stay updated with the movements of the dow jones index in the middle of the day on Friday. Discover which stocks are leading as top gainers and losers in today's session.",
                "category": "company",
                "datetime": 1780677602,
                "headline": "Friday's session: top gainers and losers in the dow jones index"
              },
              {
                "id": 140536655,
                "url": "https://finnhub.io/api/news?id=51d6e1259aaaf17c4a38dbedde4206d87f5e98dc37a37349757ceefcf1801bfb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Amgen recently received European Commission approval for IMDYLLTRA (tarlatamab) to treat adults with extensive-stage small cell lung cancer after platinum-based chemotherapy and presented fresh Phase 3 and real-world data on UPLIZNA and TAVNEOS at the EULAR 2026 Congress, reinforcing their safety and disease-control profiles in rare autoimmune conditions. Together, the new oncology authorization and autoimmune data highlight Amgen’s growing presence in high unmet-need niches, where...",
                "category": "company",
                "datetime": 1780669114,
                "headline": "Is Oncology Approval And Autoimmune Data Momentum Altering The Investment Case For Amgen (AMGN)?"
              },
              {
                "id": 140536596,
                "url": "https://finnhub.io/api/news?id=042a576ceafaf07fdfa9f23ab797e1bf9b283028a0e1e726567ffeee37c9d881",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "J&J faces Stelara erosion, China MedTech pressure and talc litigation, but targets $100B revenues and faster growth in 2026.",
                "category": "company",
                "datetime": 1780664820,
                "headline": "Can JNJ Sustain Growth Amid Patent, Legal and China Risks?"
              },
              {
                "id": 140534949,
                "url": "https://finnhub.io/api/news?id=3d91e98fb5fe4b98e59a594b47ae385c03dc0b3068cd70bcfe7dbfba5d639d0b",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1412046220/image_1412046220.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "AMGN",
                "summary": "Amgen Inc. upgraded to cautious Buy: pipeline growth drivers, margin upside, and risk/reward near lows. Click for this AMGN stock update.",
                "category": "company",
                "datetime": 1780646400,
                "headline": "Amgen: Time For An Upgrade? Yes, I Think So"
              },
              {
                "id": 140533070,
                "url": "https://finnhub.io/api/news?id=414136c74668158fa770f8798bc01ffe346a70834bfc8fa59bc6d648f16656e1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Amgen (NASDAQ:AMGN) executives used a Jefferies investor conference appearance to emphasize the company’s first-quarter growth, its late-stage pipeline and its preparations for potential launches, including the obesity candidate MariTide. Peter Griffith, executive vice president and chief financial",
                "category": "company",
                "datetime": 1780635748,
                "headline": "Amgen Touts MariTide, AI Gains and 2026 Growth Plans at Jefferies Conference"
              },
              {
                "id": 140529191,
                "url": "https://finnhub.io/api/news?id=cef88c4e5f0946619db8eea5444bae921c67c68ab802d27a88bbc6ca7403336b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Even without its metabolic business, management argues Eli Lilly (LLY) would be one of the fastest-growing pharmaceutical companies in the industry. This is not a single-product story. The company's immunology, oncology, and neuroscience medicines collectively grew by 160%, showing the depth of its R&D engine.",
                "category": "company",
                "datetime": 1780604608,
                "headline": "75% Upside For LLY Stock?"
              },
              {
                "id": 140527257,
                "url": "https://finnhub.io/api/news?id=b2f110a6328b87614466bc07b4c0c14ac9f2f322845aed7a502190c50323179d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "(Bloomberg) -- Quantinuum Inc., a quantum computing company backed by Honeywell International Inc., opened 13% above its listing price after raising $1.68 billion in an upsized US initial public offering.Most Read from BloombergGlazer Family Members Study Manchester United Stake SaleRepublican-Led House Votes to Stop Iran War, Rebuking TrumpTrump Begins Rebuilding His Tariff Wall, Citing Forced LaborBroadcom Slides by Most in More Than a Year on AI Outlook MissStock Buyers Step In to Lift Dow Av",
                "category": "company",
                "datetime": 1780595522,
                "headline": "Honeywell-Backed Quantinuum Shares Jump 13% After Upsized IPO"
              },
              {
                "id": 140524206,
                "url": "https://finnhub.io/api/news?id=5e178280abf5bb889c7bc6709bca47d65f3a252b18edc158043e32d0bcf521af",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "AMGN",
                "summary": "Stay informed about the performance of the dow jones index in the middle of the day on Thursday. Uncover the top gainers and losers in today's session for valuable insights.",
                "category": "company",
                "datetime": 1780591202,
                "headline": "Top dow jones movers in Thursday's session"
              },
              {
                "id": 140525441,
                "url": "https://finnhub.io/api/news?id=39b0bec51ff64a19eed995ed6c171b8d80cdb2e0e4517ab1af1c9284e5ff8817",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
                "category": "company",
                "datetime": 1780587006,
                "headline": "Alkermes (ALKS) Up 21.1% Since Last Earnings Report: Can It Continue?"
              },
              {
                "id": 140522926,
                "url": "https://finnhub.io/api/news?id=c55c0b1f5a8e93cc4136ec8aafc320627aa1d90f97349c0eb9127d10095cea03",
                "image": "https://www.chartmill.com/images/uploads/CM_Gap_Stocks_Small_free_ad767b11cf.webp",
                "source": "ChartMill",
                "related": "AMGN",
                "summary": "Stay updated with the S&P500 gap up and gap down stocks on Thursday. Get a glimpse of the market's movement during today's session.",
                "category": "company",
                "datetime": 1780583701,
                "headline": "Gapping S&P500 stocks in Thursday's session"
              },
              {
                "id": 140521720,
                "url": "https://finnhub.io/api/news?id=0808e1e2761df6619c24a61e075c1f4cbcc9ed6888cdea3cf541cd519ac9ec09",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Stock Market Today: The Dow Jones index rose Thursday ahead of jobless claims. Broadcom and CrowdStrike plunged on earnings.",
                "category": "company",
                "datetime": 1780580399,
                "headline": "Stock Market Today: Dow Rises, Nasdaq Falls With Jobless Data Due; Broadcom, CrowdStrike Plunge (Live Coverage)"
              },
              {
                "id": 140537433,
                "url": "https://finnhub.io/api/news?id=83ee5455b0e25ae8c35ecbafb6ee90d435b8b7f0b4e4ec13e3ddd303d7e69357",
                "image": "https://image.cnbcfm.com/api/v1/image/108316904-1780592736545-gettyimages-2279056368-QUANTINUUM_IPO.jpeg?v=1780592810&w=1920&h=1080",
                "source": "CNBC",
                "related": "AMGN",
                "summary": "Honeywell will retain a majority stake in Quantinuum and will continue to be a strategic customer and partner following the listing.",
                "category": "company",
                "datetime": 1780580311,
                "headline": "Quantinuum closes flat in Nasdaq debut, after upsized offering"
              },
              {
                "id": 140527258,
                "url": "https://finnhub.io/api/news?id=1c1eb5c8c119682b6722233a64d880d3cb4cac17be873bca6314975a287ca4d6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "HON will own a large stake in Quantinuum following the IPO.",
                "category": "company",
                "datetime": 1780580102,
                "headline": "Honeywell Stock Is Likely to Reward Shareholders Following Quantinuum IPO, Split"
              },
              {
                "id": 140524207,
                "url": "https://finnhub.io/api/news?id=bfb7f12cdaf0c8869c8dd43133a3eec78f7fbd6c17c98dcffd1295d645e5e0a4",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "AMGN",
                "summary": "Amgen Inc. (AMGN) Jefferies Global Healthcare Conference 2026 June 4, 2026 9:55 AM EDTCompany ParticipantsPeter Griffith - Executive VP & CFONarimon...",
                "category": "company",
                "datetime": 1780577517,
                "headline": "Amgen Inc. (AMGN) Presents at Jefferies Global Healthcare Conference 2026 Transcript"
              },
              {
                "id": 140524525,
                "url": "https://finnhub.io/api/news?id=43bd7c17aae8772f331a4508c54a5af2eef686618833b353083d6440f42073e7",
                "image": "https://image.cnbcfm.com/api/v1/image/108316697-17805800041780580001-46344551569-1080pnbcnews.jpg?v=1780580003&w=1920&h=1080",
                "source": "CNBC",
                "related": "AMGN",
                "summary": "CNBC’s Jim Cramer delivers his daily Mad Dash.",
                "category": "company",
                "datetime": 1780565991,
                "headline": "Cramer’s Mad Dash: CrowdStrike"
              },
              {
                "id": 140515847,
                "url": "https://finnhub.io/api/news?id=f12eae3674694cf425f50d042292f0735b68447f2c30d7b4dfe9d35bd11e5ca5",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "AMGN",
                "summary": "Join us in exploring the top gainers and losers within the dow jones index one hour before the close of the markets on Wednesday as we examine the latest happenings in today's session.",
                "category": "company",
                "datetime": 1780513802,
                "headline": "What's going on in today's session: dow jones movers"
              },
              {
                "id": 140513835,
                "url": "https://finnhub.io/api/news?id=7e1cb0184f6aeb9ddbe16925bff29adde63c5afab579bff30d0eeaf1f3ab0d26",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "AMGN",
                "summary": "Join us in exploring the top gainers and losers within the dow jones index in the middle of the day on Wednesday as we examine the latest happenings in today's session.",
                "category": "company",
                "datetime": 1780504802,
                "headline": "Top dow jones movers in Wednesday's session"
              },
              {
                "id": 140512264,
                "url": "https://finnhub.io/api/news?id=d31b14506b7a676fd50a6cf84e12f908dbc8673c957b82b755682d295e06a520",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Amgen (NASDAQ:AMGN) today announced the presentation of new data across rare autoimmune and inflammatory diseases at the European Alliance of Associations for Rheumatology (EULAR) 2026 Congress, taking place from June 3-6 in London.",
                "category": "company",
                "datetime": 1780491600,
                "headline": "AMGEN TO PRESENT NEW DATA ACROSS RARE AUTOIMMUNE AND INFLAMMATORY DISEASES AT EULAR 2026"
              },
              {
                "id": 140513866,
                "url": "https://finnhub.io/api/news?id=48033d2a01aaf2a5b70edce1909f9772afd9dd47724480021a7e44ee54924f21",
                "image": "",
                "source": "Benzinga",
                "related": "AMGN",
                "summary": "Approval Based Upon Phase 3 DeLLphi-304 Trial Demonstrating 40% Reduction in Risk of Death with IMDYLLTRA Compared to ChemotherapyNovel Treatment Option for Patients with Extensive-Stage Small Cell Lung Cancer That Has",
                "category": "company",
                "datetime": 1780479645,
                "headline": "Reported June 1, 2026: European Commission Approves Amgen's IMDYLLTRA For The Treatment Of Extensive-Stage Small Cell Lung Cancer"
              },
              {
                "id": 140506237,
                "url": "https://finnhub.io/api/news?id=45b4940920785b232e0f7dcf266a688157c99b2b45043851344ab6908cfc735a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Investors may want to keep an eye on June 3 as Quantinuum is set to price its IPO and make a big move toward its Wall Street debut.",
                "category": "company",
                "datetime": 1780414899,
                "headline": "Dear Future Quantinuum Stock Investors, Mark Your Calendars for June 3"
              },
              {
                "id": 140500555,
                "url": "https://finnhub.io/api/news?id=d5f1529902c144dd7b32fde17312009a2757759b90796e298dd1bb80a851c8ed",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "As Legend’s LB2102 trial in SCLC fails to dazzle, co-developer Novartis banks on quick manufacturing to find a commercial edge.",
                "category": "company",
                "datetime": 1780414086,
                "headline": "ASCO 2026: Mixed SCLC result for Legend’s LB2102, Novartis expedites manufacture"
              },
              {
                "id": 140502522,
                "url": "https://finnhub.io/api/news?id=f58f9f9de18c029a69e5f9027706fe609e6359f3b1f65ff08353a8169fddee68",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "AMGN wins EU approval for Imdylltra in extensive-stage small cell lung cancer after phase III data showed a 40% reduction in death risk.",
                "category": "company",
                "datetime": 1780413300,
                "headline": "Amgen Secures EU Nod for Imdylltra in Lung Cancer Indication"
              },
              {
                "id": 140500556,
                "url": "https://finnhub.io/api/news?id=1ce1d8ecb1561a7c2323d2fd942d51e4199f9ac42bf44ce2a93c6895bfc7833b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "We recently compiled a list of the 10 Popular Penny Stocks on Robinhood to Watch in 2026. TScan Therapeutics, Inc. (NASDAQ:TCRX) is one of the most popular penny stocks. TheFly reported on May 6 that TCRX announced its first-quarter 2026 financial results, covering the period ended March 31, 2026, along with a corporate update. The […]",
                "category": "company",
                "datetime": 1780408657,
                "headline": "TScan Therapeutics, Inc. (TCRX) Reports Q1 2026 Results With Improved Net Loss"
              },
              {
                "id": 140500557,
                "url": "https://finnhub.io/api/news?id=1183493ccbd38090056ee103fdee5ffe85498bf9f169172a79dc971c54869ac1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Gilead Sciences has outperformed other healthcare stocks, and analysts remain highly optimistic about the stock’s outlook",
                "category": "company",
                "datetime": 1780394015,
                "headline": "How Is Gilead Sciences's Stock Performance Compared to Other Healthcare Stocks"
              },
              {
                "id": 140488711,
                "url": "https://finnhub.io/api/news?id=a0cf5e388278863f44b3d33d9ff496286f691cf4e520d589cb681a907fe6b2fa",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "AMGN",
                "summary": "Join us in exploring the top gainers and losers within the dow jones index in the middle of the day on Monday as we examine the latest happenings in today's session.",
                "category": "company",
                "datetime": 1780332002,
                "headline": "Top dow jones movers in Monday's session"
              },
              {
                "id": 140487878,
                "url": "https://finnhub.io/api/news?id=78d000f242147f251609737764b250555ea74909dde26e15a6db062552faffb3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "The group has been funding research projects, touring factories and piloting workforce development programs. Its three co-directors shared highlights during recent events in Boston and Cambridge.",
                "category": "company",
                "datetime": 1780312620,
                "headline": "MIT bullish on its Initiative for New Manufacturing at the one-year mark"
              },
              {
                "id": 140485882,
                "url": "https://finnhub.io/api/news?id=353860638747a968a95605480e7041c29c1412360630e290f1a09fdb3141471a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other business lines such as M&A advisory.",
                "category": "company",
                "datetime": 1780308531,
                "headline": "2 Unpopular Stocks That Should Get More Attention and 1 We Question"
              },
              {
                "id": 140484269,
                "url": "https://finnhub.io/api/news?id=b2e75be58fd7ff1bc7b508b976fb5671d6711846fb84e7ccc5afb7b045bae063",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Amgen's fair value estimate has been nudged from US$349.66 to US$352.23 per share, a small move that still matters if you are tracking entry points and valuation ranges. Around that level, analysts are split, with some using higher targets such as US$427 on the back of rare disease and pipeline assets, while others sit closer to US$350 and stress that recent gains already price in a lot of the good news. Read on to see how to interpret these shifting targets and keep up with the evolving...",
                "category": "company",
                "datetime": 1780290406,
                "headline": "How The Amgen (AMGN) Story Is Evolving As Rare Disease Upside Meets Valuation Caution"
              },
              {
                "id": 140477053,
                "url": "https://finnhub.io/api/news?id=f14932eee59b5f35c752ef6ebde0b21308a2528d7427d9187aa5bf7c0224498d",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1839458057/image_1839458057.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "AMGN",
                "summary": "June 2026 Dogs of the Dow update: Verizon leads dividend value; analysts see 17%–45% gains by 2027.",
                "category": "company",
                "datetime": 1780222378,
                "headline": "The June Dog Of The Dow To Buy"
              },
              {
                "id": 140477637,
                "url": "https://finnhub.io/api/news?id=391183b0757ad387c9a173512048aa5581418d48116e785cacc2a7ca84ea628c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Due to Pfizer’s underperformance relative to its peers over the past year, Wall Street analysts remain cautious about the stock’s prospects",
                "category": "company",
                "datetime": 1780216018,
                "headline": "How Is Pfizer's Stock Performance Compared to Other Healthcare Stocks?"
              },
              {
                "id": 140476903,
                "url": "https://finnhub.io/api/news?id=e6b73b44f281cc89130a734a85885956c18abb15d459dad28212654a6cdb24f1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Despite Amgen's outperformance relative to the healthcare sector over the past year, Wall Street analysts remain cautiously optimistic about the stock’s prospects.",
                "category": "company",
                "datetime": 1780212328,
                "headline": "Amgen Stock: Is AMGN Outperforming the Healthcare Sector?"
              },
              {
                "id": 140467070,
                "url": "https://finnhub.io/api/news?id=e7f6abd288147848abef16226ac7d4117d6f24e94dd9c0698737273c81e088c5",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2249402682/image_2249402682.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "AMGN",
                "summary": "Burke & Herbert Financial (BHRB) stock: Hold rating as asset quality risks persist despite rising book value and low forward P/E. Read More here.",
                "category": "company",
                "datetime": 1780091549,
                "headline": "Burke & Herbert Financial Services Starts 2026 With Mixed Results"
              },
              {
                "id": 140466597,
                "url": "https://finnhub.io/api/news?id=fc8aa598701b4ab521071a7a9d87351db004db2fa7c1d8f993723bf90f02c3fa",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1072593728/image_1072593728.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "AMGN",
                "summary": "A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Read here for more details.",
                "category": "company",
                "datetime": 1780091549,
                "headline": "Dividend Champion, Contender, And Challenger Highlights: Week Of May 31"
              },
              {
                "id": 140464218,
                "url": "https://finnhub.io/api/news?id=0aa50610368f6bea6d9cb93a0337c7704175a92a4e003522cdc0e34bb50fcd06",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Amgen (NASDAQ:AMGN) will present at Jefferies Global Healthcare Conference at 9:55 a.m. ET on Thursday, June 4, 2026. Peter Griffith, executive vice president and chief financial officer at Amgen, Narimon Honarpour, senior vice president of global development at Amgen, and Kave Niksefat, senior vice president of Global Marketing and Access at Amgen, will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, i",
                "category": "company",
                "datetime": 1780084860,
                "headline": "AMGEN TO PRESENT AT JEFFERIES GLOBAL HEALTHCARE CONFERENCE"
              },
              {
                "id": 140460324,
                "url": "https://finnhub.io/api/news?id=d3bcd860c98f3257bdfc58fdb7a05812711aa12a57f435f9ea4fa16f8016731b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Merck & Co. has surged past the S&P 500 Index over the past year, and analysts remain somewhat optimistic about the stock’s growth potential.",
                "category": "company",
                "datetime": 1780051830,
                "headline": "Is Merck & Co. Stock Outperforming the S&P 500?"
              },
              {
                "id": 140443524,
                "url": "https://finnhub.io/api/news?id=46353dc775e3b2ee0dbd46a29e25a4597dd187fb2804bd1a5a5ccda87acc286c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Over the past year, many Amgen Inc. ( NASDAQ:AMGN ) insiders sold a significant stake in the company which may have...",
                "category": "company",
                "datetime": 1779969611,
                "headline": "Possible Bearish Signals With Amgen Insiders Disposing Stock"
              },
              {
                "id": 140443132,
                "url": "https://finnhub.io/api/news?id=d9aaa021ff58b1e856938b5e504fdd315472d2c919906cb48138449716c6d53f",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2218694968/image_2218694968.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "AMGN",
                "summary": "Screen large-cap dividend stocks using dividend yield + free cash flow yield for stronger income.",
                "category": "company",
                "datetime": 1779958800,
                "headline": "Building A $100,000 All-Weather Dividend Portfolio For May 2026"
              },
              {
                "id": 140432954,
                "url": "https://finnhub.io/api/news?id=ffa05e4b38b4492e66261f9c1464b303f6ad5d9c6ea2975386ffa08e550fd9ae",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "NVO and AMGN square off as GLP-1 leadership, pipeline depth and diversification shape a compelling healthcare stock comparison.",
                "category": "company",
                "datetime": 1779892320,
                "headline": "Novo Nordisk vs. Amgen: Which Pharma Stock Is the Better Buy?"
              },
              {
                "id": 140438560,
                "url": "https://finnhub.io/api/news?id=9e77dde27a25eb4f35dedad48b73eb26dc66e0ab3b387357c71133026ad15428",
                "image": "",
                "source": "Benzinga",
                "related": "AMGN",
                "summary": "Ember LifeSciences, Inc., ("Ember") a leading provider of revolutionary cold chain technology, today announced strategic investments from Amgen Ventures, the corporate venture arm of Amgen (NASDAQ: AMGN) a",
                "category": "company",
                "datetime": 1779872645,
                "headline": "Amgen Ventures Invests In Ember LifeSciences; Terms Undisclosed"
              },
              {
                "id": 140426075,
                "url": "https://finnhub.io/api/news?id=507b6490bd8c0ae06443ad12e6dc7097fb8083dfbb049e510ac3ab8f6b7cf925",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "RTX builds a $271B backlog on defense demand and recovering air travel, but tariffs and supply-chain issues cloud growth.",
                "category": "company",
                "datetime": 1779828300,
                "headline": "Top Stock Reports for RTX, Wells Fargo & Amgen"
              },
              {
                "id": 140421291,
                "url": "https://finnhub.io/api/news?id=991eda35ed0f7803994c62c787ca72f714678b04ddc47647435e666a14d4c699",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "The Dow gave back its opening gains, with healthcare stocks a big drag.  The blue-chip index was trading flat, while the S&P 500 was up 0.9%, and the Nasdaq rose 1.4%.  UnitedHealth Group and Amgen, among the Dow's top five stocks, were down by nearly 3% and 0.4%, respectively.",
                "category": "company",
                "datetime": 1779807055,
                "headline": "Dow Gives Back Early Gains. Healthcare Stocks Are a Drag."
              },
              {
                "id": 140421268,
                "url": "https://finnhub.io/api/news?id=016fe4716524e8a1ce70084bae1d4a98756e919f586fa44dc1b97d2b398a3832",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Amgen faces LOE headwinds and pricing pressure, yet key growth drugs and biosimilars continue gaining traction.",
                "category": "company",
                "datetime": 1779801660,
                "headline": "AMGN Stock Down 13% in 3 Months: Buy the Dip or Book Profits?"
              },
              {
                "id": 140422063,
                "url": "https://finnhub.io/api/news?id=97f79260ed7d3e8c68c431cbf7f970598d2eef6fddc53c3065581632ce82c98c",
                "image": "https://image.cnbcfm.com/api/v1/image/108312041-17798133331779813331-46177641065-1080pnbcnews.jpg?v=1779813333&w=1920&h=1080",
                "source": "CNBC",
                "related": "AMGN",
                "summary": "The Investment Committee debate the latest Calls of the Day.",
                "category": "company",
                "datetime": 1779800524,
                "headline": "Calls of the Day: Eli Lilly, UnitedHealth and the XBI"
              },
              {
                "id": 140422770,
                "url": "https://finnhub.io/api/news?id=c215adea6cd26d3e2ad2b723b1e8f92b1c9451cbc04d959e1ec8133bfa933a8d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "The base editing medicine lowered “bad” cholesterol levels along with a key protein, clearing the way for a Phase 2 study.",
                "category": "company",
                "datetime": 1779796590,
                "headline": "Early data for heart drug affirm Lilly’s billion-dollar bet on Verve"
              },
              {
                "id": 140419468,
                "url": "https://finnhub.io/api/news?id=880b9f64ea279b09c90fde8a4af61ee0e1a0ce9bf2516dee294d7381f4971fe9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "(Bloomberg) -- Quantinuum Inc., a quantum computing company backed by Honeywell International Inc., is seeking to raise $1.05 billion in its US initial public offering, capitalizing on investor enthusiasm for the technology. Most Read from BloombergNvidia CEO Urges Super Micro to Tighten Up on ComplianceTrump Doctor Visit Renews Health Scrutiny as 80th Birthday NearsTrump Says He’ll Announce Negotiated Deal With Iran ShortlyRubio Sees Good News Coming on Hormuz as Iran Talks ContinueUS, Iran Inc",
                "category": "company",
                "datetime": 1779793200,
                "headline": "Honeywell-Backed Quantinuum Seeks to Raise $1.05 Billion in IPO"
              },
              {
                "id": 140420040,
                "url": "https://finnhub.io/api/news?id=6199c57dd88ad5e67cfefae9bcb6fb7be77fb5695ae55c400e4584cf40b22feb",
                "image": "",
                "source": "SeekingAlpha",
                "related": "AMGN",
                "summary": "",
                "category": "company",
                "datetime": 1779788726,
                "headline": "Amgen's Growth Engine Is Just Getting Started"
              },
              {
                "id": 140418479,
                "url": "https://finnhub.io/api/news?id=033ee5053bd5fcab3275af378c0f026c1f9286457cd796789afc4b094a0db26a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "The Dow is no longer dominated by industrial, energy, manufacturing, and consumer goods companies.",
                "category": "company",
                "datetime": 1779780000,
                "headline": "3 Blue Chip Dividend Stocks to Buy in June as the Dow Jones Industrial Average Turns 130"
              },
              {
                "id": 140413355,
                "url": "https://finnhub.io/api/news?id=2b8e038b3bdd0b54b921e7e1240a8d8307597e8a2e517f89938282314741491c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Amgen Inc. (NASDAQ:AMGN) is one of the cheap NASDAQ stocks to buy right now. On May 19, Amgen announced the retirement of its Executive Vice President and Chief Financial Officer, Peter Griffith, who has held the role since 2020. During his tenure, Griffith was instrumental in strengthening the company’s financial position, supporting capital allocation, and […]",
                "category": "company",
                "datetime": 1779738889,
                "headline": "Amgen (AMGN) Announces Retirement of CFO Peter Griffith"
              },
              {
                "id": 140415133,
                "url": "https://finnhub.io/api/news?id=1e6d0b3e195f0946512a491e07c15e1b37a2e8176086e061e9317ebff0c51877",
                "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/aggregated_options_3.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "AMGN",
                "summary": " ",
                "category": "company",
                "datetime": 1779716150,
                "headline": "10 Health Care Stocks With Whale Alerts In Today's Session"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 8,
            "negative_hits": 0,
            "positive_hits": 2,
            "recomputed_at_score": true,
            "sentiment_score_raw": 0.6,
            "source_article_count": 111,
            "discarded_article_count": 93
          },
          "sentimentPoints": 4
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 23.5,
        "grade": "良好",
        "items": {
          "bbPoints": 3,
          "adxPoints": 3,
          "sarPoints": 2.4000000000000004,
          "vcpPoints": 1.4,
          "macdPoints": 4,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 1.4,
            "vcp_reason": "站上MA50；升放量(近10日5日)；收盤突破20日高位；Ready=N；Confirm=Y",
            "vcp_metrics": {
              "up_days": 7,
              "vol_ref": 2805183.3333333335,
              "down_days": 2,
              "vcp_ready": false,
              "above_ma50": true,
              "avg_vol_10": 2862800,
              "avg_vol_20": 2466130,
              "avg_vol_30": 2805183.3333333335,
              "range_pct_10": 0.08721387660213256,
              "range_pct_20": 0.09171125777891208,
              "range_pct_30": 0.10827729396910798,
              "up_expand_ok": true,
              "lookback_used": 79,
              "near_20d_high": true,
              "contraction_ok": false,
              "down_shrink_ok": false,
              "up_expand_days": 5,
              "breakout_20d_ok": true,
              "vol_ratio_10_30": 1.020539358687192,
              "dist_to_20d_high": -0.002539794039888109,
              "down_shrink_days": 2,
              "breakout_level_20d": 350.42999,
              "vcp_breakout_confirm": true,
              "contraction_ratio_10_30": 0.8054678262186261
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": false
          },
          "kdjAdxPoints": 0.7,
          "rsiKdjPoints": 3.2,
          "volumeWeight": 2,
          "maCrossPoints": 3.2,
          "shortRsiPoints": 0.4,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 0.6,
          "volumePointsTechnical": 1.2
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "優秀",
        "items": {
          "position": {
            "score": 1.8,
            "details": {
              "atrPct": 2.4387736980879624,
              "turnoverUsdM": 1148.675904696,
              "liquidityPoints": 0.8,
              "volatilityPoints": 1
            }
          },
          "rrPoints": 2.4,
          "stopLevels": {
            "symbol": "US.AMGN",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 334.1842,
            "strength_details": {
              "ma_score": 3,
              "atr_score": 2,
              "rsi_score": 3,
              "macd_score": 3,
              "volume_score": 2
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 2.2,
            "stop_loss_percent": 4.9,
            "take_profit_price": 389.1616,
            "target_multiplier": 2.5,
            "technical_strength": 2.65,
            "take_profit_percent": 10.8
          },
          "positionPoints": 1.8,
          "stopLossPoints": 2.4,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 2.214227586689854,
          "stopLossPercent": 4.877547396175925,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": true,
    "missingFields": [],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 100,
    "atr": {
      "atr": 8.5679,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 6,
      "atr_pct": 2.44
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "超買或超賣風險",
      "score": 2,
      "value": 164.52
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "資金流入",
      "score": 8,
      "value": 0.2544
    },
    "kdj": {
      "d": 75.6,
      "j": 108.6,
      "k": 86.6,
      "rule": "Cursor_18.24 K/D cross",
      "score": 4,
      "signal": "金叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "入貨中",
      "score": 8,
      "value": 64.16
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 10,
      "trend": "強流入",
      "value": 58216700,
      "recentSlope": 2300500,
      "previousSlope": -684100
    },
    "rsi": 67.49,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 8,
      "trend": "上升",
      "value": 324.2724,
      "position": "SAR喺價下",
      "distancePct": 7.7,
      "previousTrend": "上升"
    },
    "ma50": 332.9022,
    "macd": {
      "macd": 5.179952746495076,
      "trend": "強烈看漲",
      "signal": 2.8535416954038055,
      "histogram": 2.32641105109127
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 10,
      "value": 333.9202,
      "position": "連續5日>VWAP",
      "consecutiveAbove": 9
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "有量",
      "ratio": 1.26,
      "score": 6,
      "avgVolume": 2589980,
      "currentVolume": 3269600
    },
    "derived": {
      "ma20": 333.4345,
      "ma50": 332.9022,
      "prevClose": 349.69,
      "avgVolume10": 2943700,
      "avgVolume20": 2589980,
      "changePercent": 0.47,
      "avgVolumeForScore": 2589980
    },
    "ma_cross": {
      "ma20": 333.4345,
      "ma50": 332.9022,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "上穿",
      "score": 8,
      "prevMa20": 332.515,
      "prevMa50": 332.6014,
      "spreadPct": 0.16,
      "isVolumeBreakout": false
    },
    "bollinger": {
      "lower": 315.5104,
      "upper": 351.3586,
      "position": "上半部"
    },
    "rsi_short": 90.92,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 1.26
    }
  }
}

{
  "close": 351.32,
  "volume": 3269600,
  "changePercent": 0.47
}